A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC

Active:	Yes
Cancer Type:		NCT ID:	NCT05849298
Trial Phases:	Phase II	Protocol IDs:	CAAA617B12203 (primary) NCI-2024-10339 2022-503040-41-00
Eligibility:	18 - 100 Years, Male	Study Type:	Treatment
Study Sponsor:	Novartis Pharmaceuticals Corporation
NCI Full Details:	http://clinicaltrials.gov/show/NCT05849298

Summary

The purpose of this study is to evaluate the efficacy and safety of AAA617 alone
(Lutetium [177Lu] vipivotide tetraxetan) and in combination with an Androgen Receptor
Pathway Inhibitors (ARPI) in participants with PSMA-positive, castration-resistant
prostate cancer and no evidence of metastasis in conventional imaging (CI) (i.e., CT/MRI
and bone scans). Approximately 120 participants will be randomized.

Treatment Sites in Georgia

University Cancer and Blood Center, LLC - Athens Medical Oncology
3320 Old Jefferson Road
Building 800
Athens, GA 30607
www.universitycancer.com

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.